W
WAVEMAN · COMPANY
MXCT · Maxcyte, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

MXCT

MAXCYTE, INC.
PHARMA & BIOTECH · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · CIK 0001287098
ACTIVIST 13D☆ WATCH
INSIDER NET · 180D
-$8.3K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
79
13F, latest reported quarter
REVENUE GROWTH
-5.7%
XBRL, annual
NET MARGIN
-213.0%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$8.3K over 180 days
more than 63% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
79 funds added or opened last quarter
more than 57% of Pharma & Biotech
REVENUE
-5.7% year over year
below 66% of Pharma & Biotech
MARGIN
-213.0% net margin
below 73% of Pharma & Biotech
BUYBACKS
$1.5M repurchased, FY to 2026-06-30
below 86% of Pharma & Biotech
SHORT
1.2% of shares outstanding short · 1.6 days to cover · settled 2026-07-31
below 70% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
79 funds added or opened positions in the latest 13F quarter, of 124 holders.
RIVER GLOBAL INVESTORS LLP disclosed a 5%+ stake (0.8%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -6.0%
-6.0%12M
-50%-21%+8%+37%2025-092025-102025-122026-032026-052026-072026-09 2026-03-17 · Swirsky Douglas J sold $8.3K2026-08-04 · RIVER GLOBAL INVESTORS LLP filed a 5%+ stake (0.8%)2026-05-14 · RIVER GLOBAL INVESTORS LLP filed a 5%+ stake (6.1%)
INSIDER SELL13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
An activist crossed the 5% line with declared intent.
The record shows a net $8.3K sold by insiders over 180 days, 79 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, MAXCYTE, INC. insiders sold a net $8.3K of stock across 106 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Swirsky Douglas J
CHIEF FINANCIAL OFFICER
SELL
2026-03-17
10,142.0
$8.3K
Swirsky Douglas J
CHIEF FINANCIAL OFFICER
BUY
2025-08-13
50,000.0
$64.5K
Masoud Maher
President and CEO
BUY
2025-08-13
75,000.0
$102.8K
Erck Stanley C
Director
BUY
2025-08-13
100,000.0
$137.0K
DOUGLAS RICHARD
Director
BUY
2025-08-13
80,000.0
$111.2K
106 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 101 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Capricorn Fund Managers Ltd
8,200,000.0 sh
$10.1M
Vitruvian Partners LLP
5,043,356.0 sh
$6.2M
VANGUARD CAPITAL MANAGEMENT LLC
4,031,284.0 sh
$5.0M
MORGAN STANLEY
3,694,049.0 sh
$4.5M
Mudita Advisors LLP
3,370,689.0 sh
$4.1M
5%+ owners
13D = intent to influence · 13G = passive
RIVER GLOBAL INVESTORS LLP
ACTIVIST 13D · 2026-08-04
0.8%
RIVER GLOBAL INVESTORS LLP
ACTIVIST 13D · 2026-05-14
6.1%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Invesco NASDAQ Future Gen 200 ETF
$30.5K POSITION · AS OF 2026-02-28
0.2%
Inception Portfolio
$244.1K POSITION · AS OF 2026-03-31
0.1%
ALGER SMALL CAP GROWTH FUND
$166.1K POSITION · AS OF 2026-04-30
0.1%
ALGER SMALL CAP GROWTH INSTITUTIONAL FUND
$53.6K POSITION · AS OF 2026-04-30
0.1%
Alger Small Cap Growth Portfolio
$95.2K POSITION · AS OF 2026-03-31
0.1%
VOYA INDEX PLUS SMALLCAP PORTFOLIO
$170.2K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$21.0M$22.2M$19.5M$28.7M
GROSS PROFIT$26.8M$31.5M$36.5M$39.2M
OPERATING INCOME$-51.9M$-51.2M$-48.3M$-27.4M
NET INCOME$-44.6M$-41.1M$-37.9M$-23.6M
EPS (DILUTED)-0.42-0.39-0.37-0.23
OPERATING CASH FLOW$-34.4M$-27.6M$-21.7M$-14.8M
CASH$20.1M$27.9M$46.5M$11.1M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →